Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
Identifieur interne : 005090 ( PubMed/Corpus ); précédent : 005089; suivant : 005091Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
Auteurs : J G De Yebenes ; S. Fahn ; S. Lovelle ; V. Jackson-Lewis ; P. Jorge ; M A Mena ; J. Reiriz ; J C Bustos ; C. Magari Os ; A. MartinezSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1987.
English descriptors
- KwdEn :
- Animals, Brain (drug effects), Corpus Striatum (drug effects), Dopamine (administration & dosage), Dopamine (metabolism), Dopamine Agents (administration & dosage), Infusion Pumps, Injections, Intraventricular (instrumentation), Lisuride (administration & dosage), Macaca fascicularis, Male, Neural Pathways (drug effects), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (drug therapy), Pergolide (administration & dosage), Rats, Receptors, Dopamine (drug effects), Selegiline (administration & dosage), Stereotyped Behavior (drug effects), Substantia Nigra (drug effects).
- MESH :
- chemical , administration & dosage : Dopamine, Dopamine Agents, Lisuride, Pergolide, Selegiline.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Brain, Corpus Striatum, Neural Pathways, Receptors, Dopamine, Stereotyped Behavior, Substantia Nigra.
- drug therapy : Parkinson Disease, Secondary.
- instrumentation : Injections, Intraventricular.
- chemical , metabolism : Dopamine.
- Animals, Infusion Pumps, Macaca fascicularis, Male, Rats.
Abstract
We studied the effect of intracerebroventricular infusion of dopamine and dopamine agonists in rat and primate models of Parkinson's disease as an experimental approach to the treatment of levodopa-induced fluctuations. The infusion of dopamine, lisuride, and pergolide into the ventricle ipsilateral to the lesion, by 6-hydroxydopamine, of the nigrostriatal pathway induced a contralateral rotation which was maximal 24-48 h after infusion and whose intensity progressively decreased over the period of 1 week. [3H]Spiperone binding was decreased by the infusion of dopamine but the responses to subcutaneous apomomorphine were unchanged. The infusion of dopamine also restored the levels of monoamines in the rat brain. In chronic reserpized rats, the infusion of dopamine restored brain levels of dopamine but did not reverse akinesia unless monoamine oxidase inhibitors were simultaneously administered, either systemically or intracerebroventricularly. Lisuride and pergolide proved much weaker than dopamine in reversing the effects of reserpine. Intracerebroventricular infusion of dopamine plus deprenyl reversed MPTP induced akinesia in monkeys but the pump used for the delivery was not well tolerated, because of its size, by the animals.
DOI: 10.1002/mds.870020302
PubMed: 2904648
Links to Exploration step
pubmed:2904648Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.</title><author><name sortKey="De Yebenes, J G" sort="De Yebenes, J G" uniqKey="De Yebenes J" first="J G" last="De Yebenes">J G De Yebenes</name><affiliation><nlm:affiliation>Department of Neurology, Columbia University College of Physicians & Surgeons, New York, NY.</nlm:affiliation></affiliation></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name></author><author><name sortKey="Lovelle, S" sort="Lovelle, S" uniqKey="Lovelle S" first="S" last="Lovelle">S. Lovelle</name></author><author><name sortKey="Jackson Lewis, V" sort="Jackson Lewis, V" uniqKey="Jackson Lewis V" first="V" last="Jackson-Lewis">V. Jackson-Lewis</name></author><author><name sortKey="Jorge, P" sort="Jorge, P" uniqKey="Jorge P" first="P" last="Jorge">P. Jorge</name></author><author><name sortKey="Mena, M A" sort="Mena, M A" uniqKey="Mena M" first="M A" last="Mena">M A Mena</name></author><author><name sortKey="Reiriz, J" sort="Reiriz, J" uniqKey="Reiriz J" first="J" last="Reiriz">J. Reiriz</name></author><author><name sortKey="Bustos, J C" sort="Bustos, J C" uniqKey="Bustos J" first="J C" last="Bustos">J C Bustos</name></author><author><name sortKey="Magari Os, C" sort="Magari Os, C" uniqKey="Magari Os C" first="C" last="Magari Os">C. Magari Os</name></author><author><name sortKey="Martinez, A" sort="Martinez, A" uniqKey="Martinez A" first="A" last="Martinez">A. Martinez</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1987">1987</date><idno type="RBID">pubmed:2904648</idno><idno type="pmid">2904648</idno><idno type="doi">10.1002/mds.870020302</idno><idno type="wicri:Area/PubMed/Corpus">005090</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.</title><author><name sortKey="De Yebenes, J G" sort="De Yebenes, J G" uniqKey="De Yebenes J" first="J G" last="De Yebenes">J G De Yebenes</name><affiliation><nlm:affiliation>Department of Neurology, Columbia University College of Physicians & Surgeons, New York, NY.</nlm:affiliation></affiliation></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name></author><author><name sortKey="Lovelle, S" sort="Lovelle, S" uniqKey="Lovelle S" first="S" last="Lovelle">S. Lovelle</name></author><author><name sortKey="Jackson Lewis, V" sort="Jackson Lewis, V" uniqKey="Jackson Lewis V" first="V" last="Jackson-Lewis">V. Jackson-Lewis</name></author><author><name sortKey="Jorge, P" sort="Jorge, P" uniqKey="Jorge P" first="P" last="Jorge">P. Jorge</name></author><author><name sortKey="Mena, M A" sort="Mena, M A" uniqKey="Mena M" first="M A" last="Mena">M A Mena</name></author><author><name sortKey="Reiriz, J" sort="Reiriz, J" uniqKey="Reiriz J" first="J" last="Reiriz">J. Reiriz</name></author><author><name sortKey="Bustos, J C" sort="Bustos, J C" uniqKey="Bustos J" first="J C" last="Bustos">J C Bustos</name></author><author><name sortKey="Magari Os, C" sort="Magari Os, C" uniqKey="Magari Os C" first="C" last="Magari Os">C. Magari Os</name></author><author><name sortKey="Martinez, A" sort="Martinez, A" uniqKey="Martinez A" first="A" last="Martinez">A. Martinez</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1987" type="published">1987</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Brain (drug effects)</term><term>Corpus Striatum (drug effects)</term><term>Dopamine (administration & dosage)</term><term>Dopamine (metabolism)</term><term>Dopamine Agents (administration & dosage)</term><term>Infusion Pumps</term><term>Injections, Intraventricular (instrumentation)</term><term>Lisuride (administration & dosage)</term><term>Macaca fascicularis</term><term>Male</term><term>Neural Pathways (drug effects)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (drug therapy)</term><term>Pergolide (administration & dosage)</term><term>Rats</term><term>Receptors, Dopamine (drug effects)</term><term>Selegiline (administration & dosage)</term><term>Stereotyped Behavior (drug effects)</term><term>Substantia Nigra (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine</term><term>Dopamine Agents</term><term>Lisuride</term><term>Pergolide</term><term>Selegiline</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term><term>Corpus Striatum</term><term>Neural Pathways</term><term>Receptors, Dopamine</term><term>Stereotyped Behavior</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Injections, Intraventricular</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Infusion Pumps</term><term>Macaca fascicularis</term><term>Male</term><term>Rats</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We studied the effect of intracerebroventricular infusion of dopamine and dopamine agonists in rat and primate models of Parkinson's disease as an experimental approach to the treatment of levodopa-induced fluctuations. The infusion of dopamine, lisuride, and pergolide into the ventricle ipsilateral to the lesion, by 6-hydroxydopamine, of the nigrostriatal pathway induced a contralateral rotation which was maximal 24-48 h after infusion and whose intensity progressively decreased over the period of 1 week. [3H]Spiperone binding was decreased by the infusion of dopamine but the responses to subcutaneous apomomorphine were unchanged. The infusion of dopamine also restored the levels of monoamines in the rat brain. In chronic reserpized rats, the infusion of dopamine restored brain levels of dopamine but did not reverse akinesia unless monoamine oxidase inhibitors were simultaneously administered, either systemically or intracerebroventricularly. Lisuride and pergolide proved much weaker than dopamine in reversing the effects of reserpine. Intracerebroventricular infusion of dopamine plus deprenyl reversed MPTP induced akinesia in monkeys but the pump used for the delivery was not well tolerated, because of its size, by the animals.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">2904648</PMID><DateCreated><Year>1989</Year><Month>01</Month><Day>19</Day></DateCreated><DateCompleted><Year>1989</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>3</Issue><PubDate><Year>1987</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>143-58</MedlinePgn></Pagination><Abstract><AbstractText>We studied the effect of intracerebroventricular infusion of dopamine and dopamine agonists in rat and primate models of Parkinson's disease as an experimental approach to the treatment of levodopa-induced fluctuations. The infusion of dopamine, lisuride, and pergolide into the ventricle ipsilateral to the lesion, by 6-hydroxydopamine, of the nigrostriatal pathway induced a contralateral rotation which was maximal 24-48 h after infusion and whose intensity progressively decreased over the period of 1 week. [3H]Spiperone binding was decreased by the infusion of dopamine but the responses to subcutaneous apomomorphine were unchanged. The infusion of dopamine also restored the levels of monoamines in the rat brain. In chronic reserpized rats, the infusion of dopamine restored brain levels of dopamine but did not reverse akinesia unless monoamine oxidase inhibitors were simultaneously administered, either systemically or intracerebroventricularly. Lisuride and pergolide proved much weaker than dopamine in reversing the effects of reserpine. Intracerebroventricular infusion of dopamine plus deprenyl reversed MPTP induced akinesia in monkeys but the pump used for the delivery was not well tolerated, because of its size, by the animals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Yebenes</LastName><ForeName>J G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University College of Physicians & Surgeons, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fahn</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lovelle</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jackson-Lewis</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Jorge</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mena</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Reiriz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bustos</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Magariños</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>14611-51-9</RegistryNumber><NameOfSubstance UI="D012642">Selegiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>24MJ822NZ9</RegistryNumber><NameOfSubstance UI="D010479">Pergolide</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0QN3D755O</RegistryNumber><NameOfSubstance UI="D008090">Lisuride</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D007260">Infusion Pumps</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007276">Injections, Intraventricular</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000295">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008090">Lisuride</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008252">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009434">Neural Pathways</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010479">Pergolide</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011954">Receptors, Dopamine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012642">Selegiline</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013239">Stereotyped Behavior</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013378">Substantia Nigra</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2904648</ArticleId><ArticleId IdType="doi">10.1002/mds.870020302</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005090 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 005090 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:2904648
|texte= Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:2904648" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |